In this article, we are going to take a look at where Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stands against the other one-dollar stocks. The upward trend in the stock market has resumed ...

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.36 per share a year ago.

$KPTI insiders have traded $KPTI stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

NEWTON, Mass., April 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...